Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection?
作者信息
Scheen André J
机构信息
Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium.
Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège, Belgium.
出版信息
Ann Transl Med. 2018 Nov;6(Suppl 1):S68. doi: 10.21037/atm.2018.10.39.
Abstract
摘要
相似文献
1
Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection?2型糖尿病患者中2型钠-葡萄糖协同转运蛋白抑制剂对肝脏脂肪的影响：肝脏是否具有超越心血管和肾脏保护的作用？
Ann Transl Med. 2018 Nov;6(Suppl 1):S68. doi: 10.21037/atm.2018.10.39.
2
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
3
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.SGLT2 抑制剂在心血管疾病和肾功能障碍中的保护作用机制。
Curr Top Med Chem. 2019;19(20):1818-1849. doi: 10.2174/1568026619666190828161409.
4
Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.钠-葡萄糖共转运蛋白 2 抑制剂对糖尿病肾病的肾脏保护作用及其机制。
J Diabetes Complications. 2018 Jul;32(7):720-725. doi: 10.1016/j.jdiacomp.2018.04.011. Epub 2018 May 5.
5
Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management…and potentially beyond.使用2型钠-葡萄糖协同转运蛋白抑制剂实现心血管和肾脏保护：2型糖尿病管理的新范式……甚至可能超越此范畴。
Ann Transl Med. 2019 Jul;7(Suppl 3):S132. doi: 10.21037/atm.2019.05.82.
6
The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂在 2 型糖尿病心力衰竭和慢性肾脏病中的作用。
Curr Med Res Opin. 2019 Jul;35(7):1283-1295. doi: 10.1080/03007995.2019.1576479. Epub 2019 Feb 15.
7
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering.钠-葡萄糖协同转运蛋白2抑制剂：除降糖作用外的潜在抗动脉粥样硬化效应
J Clin Med Res. 2016 Jan;8(1):10-4. doi: 10.14740/jocmr2385w. Epub 2015 Dec 3.
8
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.钠-葡萄糖协同转运蛋白2抑制剂在糖尿病治疗中的应用：心血管和肾脏效应、潜在机制及临床应用
Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28.
9
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂对 2 型糖尿病成人患者心血管事件、死亡和主要安全性结局的影响：系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2016 May;4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8. Epub 2016 Mar 18.
10
[The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].[作用机制与临床潜力：钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂治疗糖尿病肾病]
Sheng Li Xue Bao. 2018 Dec 25;70(6):663-669.
引用本文的文献
1
Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).代谢功能障碍相关脂肪性肝病（MASLD）时代非酒精性脂肪性肝病（NAFLD）的病理演变与内科管理
Cureus. 2025 Jun 29;17(6):e86963. doi: 10.7759/cureus.86963. eCollection 2025 Jun.
2
Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis.探索非酒精性脂肪性肝病的潜在疗法：一项ClinicalTrials.gov分析
Diabetes Metab Syndr Obes. 2024 Feb 2;17:545-561. doi: 10.2147/DMSO.S448476. eCollection 2024.
3
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.钠-葡萄糖共转运蛋白 2 抑制剂对非酒精性脂肪性肝病肝脂肪变性/纤维化/炎症及氧化还原平衡的影响。
World J Gastroenterol. 2022 Jul 14;28(26):3243-3257. doi: 10.3748/wjg.v28.i26.3243.
4
Genetic and Life Style Risk Factors for Recurrent Non-alcoholic Fatty Liver Disease Following Liver Transplantation.肝移植后复发性非酒精性脂肪性肝病的遗传和生活方式风险因素
Front Nutr. 2022 Jan 14;8:787430. doi: 10.3389/fnut.2021.787430. eCollection 2021.
5
Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management.移植后糖尿病和原有肝脏疾病——影响治疗和管理的双向关系。
World J Gastroenterol. 2020 Jun 7;26(21):2740-2757. doi: 10.3748/wjg.v26.i21.2740.
6
Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview.非酒精性脂肪性肝病的病理生理学、分子和治疗问题概述。
Int J Mol Sci. 2019 Apr 20;20(8):1948. doi: 10.3390/ijms20081948.
本文引用的文献
1
Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.降糖药物对 2 型糖尿病患者替代终点和肾脏硬终点临床结局的影响。
Diabetes Metab. 2019 Apr;45(2):110-121. doi: 10.1016/j.diabet.2018.10.003. Epub 2018 Oct 25.
2
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2018 年美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）共识报告：2 型糖尿病患者高血糖管理。
Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4.
3
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease.钠-葡萄糖协同转运蛋白 2 抑制剂对全身和组织低度炎症的影响：对糖尿病并发症和心血管疾病的潜在贡献。
Diabetes Metab. 2018 Dec;44(6):457-464. doi: 10.1016/j.diabet.2018.09.005. Epub 2018 Sep 26.
4
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.全球视角下的非酒精性脂肪性肝病和非酒精性脂肪性肝炎。
Hepatology. 2019 Jun;69(6):2672-2682. doi: 10.1002/hep.30251.
5
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.评估钠-葡萄糖共转运蛋白 2 抑制剂达格列净对 2 型糖尿病合并非酒精性脂肪性肝病患者肝脂肪变性和纤维化的影响：应用瞬时弹性成像技术。
Diabetes Obes Metab. 2019 Feb;21(2):285-292. doi: 10.1111/dom.13520. Epub 2018 Oct 2.
6
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.非酒精性脂肪性肝病：病因、诊断、心血管代谢后果和治疗策略。
Lancet Diabetes Endocrinol. 2019 Apr;7(4):313-324. doi: 10.1016/S2213-8587(18)30154-2. Epub 2018 Aug 30.
7
SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.钠-葡萄糖共转运蛋白 2 抑制剂和肠促胰岛素药物：与 2 型糖尿病患者丙氨酸氨基转移酶活性的相关性。
Diabetes Metab. 2018 Dec;44(6):493-499. doi: 10.1016/j.diabet.2018.08.001. Epub 2018 Aug 24.
8
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.恩格列净与肝酶改善相关，这可能与肝脂肪减少有关：来自随机试验的结果，包括 EMPA-REG OUTCOME®试验。
Diabetologia. 2018 Oct;61(10):2155-2163. doi: 10.1007/s00125-018-4702-3. Epub 2018 Jul 31.
9
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.达格列净和 n-3 羧酸对 2 型糖尿病患者非酒精性脂肪性肝病的影响：一项双盲随机安慰剂对照研究。
Diabetologia. 2018 Sep;61(9):1923-1934. doi: 10.1007/s00125-018-4675-2. Epub 2018 Jul 3.
10
Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials.卡格列净对2型糖尿病患者脂肪肝指标的影响：一项随机对照试验的荟萃分析。
J Pharm Pharm Sci. 2018;21(1):222-235. doi: 10.18433/jpps29831.
Zotero 插件